Cytokinetics (CYTK) Q3 2026 earnings review
Cytokinetics heart drug sales nearly double, but cash burn stays high
Cytokinetics, a developer of heart-muscle medicines, grew US sales of its new heart drug fast while its operating costs kept climbing. US product sales of Myqorzo rose 87% from last quarter to $43 million as total patients receiving the medicine passed 2,800. Chief executive Robert I. Blum said adoption grew across more doctors, and the company kept its full-year spending plan unchanged.
| Myqorzo net product revenue | $44.5M +75.7% from last quarter |
|---|---|
| Patients dispensed Myqorzo | >2,800 1,500 at end of Q2 |
| Net loss, excluding one-offs | $190.1M +2.8% from a year ago |
| Full-year R&D and SG&A outlook | Unchanged middle of the range: $875M |
⚖️ Verdict: 🟢 Bullish
The story got better because US revenue grew at the exact same pace as the number of patients receiving the drug, easing fears that second-quarter sales were mostly distributor stocking. The company also stayed on schedule to file for US approval in a second heart condition, non-obstructive HCM, before year-end. One caution: European sales fell 39% from last quarter after initial German inventory stocking, and by our math the full-year expense plan leaves a 22% spending jump for the fourth quarter.
The question now is whether the fourth-quarter filing for non-obstructive HCM will secure a broad label without stricter safety monitoring rules. Supporters see the positive trial results opening a larger patient group with no direct rival, while skeptics worry a 10% rate of reduced heart pumping function in the study will limit adoption. The FDA's filing acceptance and review designation in early 2027 will provide the first regulatory read.
🐂 Bull Case
US Heart Drug Sales Nearly Doubled in Q3
Myqorzo is Cytokinetics' newly approved drug for obstructive hypertrophic cardiomyopathy (oHCM), a condition where thickened heart muscle blocks blood flow. Chief executive Robert I. Blum said "the launch of MYQORZO continued to build solid momentum and increased velocity with growing adoption across a broadening base of prescribers". Skeptics worried that second-quarter sales of $23.0 million in the United States relied on wholesale stocking rather than patient demand.
- US net product revenue: $43.1 million, up 87.4% from last quarter by our math
- Total patients dispensed Myqorzo: over 2,800 by quarter-end, up from 1,500 in June
- Unique prescribing doctors: nearly 1,100, up from 700 in June
Third-quarter US revenue grew at the exact same pace as the cumulative patient count, which rose 86.7% from last quarter by our math. That close match shows patient refills and roughly 1,300 new patient additions drove the quarter, rather than just distributor inventory building.
What to watch: management's commentary on US distributor inventory levels and patient continuation rates in the quarterly filing. Steady inventory weeks on hand would confirm that revenue tracks underlying patient demand.
Second Heart Indication Stays on Track for Q4 Filing
Cytokinetics wants to expand Myqorzo into non-obstructive hypertrophic cardiomyopathy (nHCM), a form of thickened heart muscle without blood-flow blockage that has no approved myosin-inhibitor rival. Blum said the drug could become the "first and only cardiac myosin inhibitor approved across the full spectrum of HCM".
During the third quarter, the drugmaker presented Phase 3 ACACIA-HCM trial results at the European Society of Cardiology Congress, published the study in the New England Journal of Medicine, and finished the trial's Japanese patient cohort. It reaffirmed plans to file a supplemental US application in the fourth quarter of 2026 and a European application in early 2027.
What to watch: confirmation of the US regulatory submission before year-end and whether the agency grants priority review. Acceptance of the filing sets the timeline for a potential commercial launch in 2027.
UK and Canada Approvals Expand International Reach
Expanding outside the United States is central to the cardiovascular drugmaker's growth plan. In the third quarter, regulators in the United Kingdom and Canada approved Myqorzo for adults with symptomatic oHCM, and Britain's cost-effectiveness agency recommended the drug for coverage in England and Wales.
The company plans to launch in the United Kingdom in the fourth quarter of 2026 and in additional countries in 2027. Partner Bayer also completed the main treatment period of its Phase 3 trial in Japan, while the adolescent cohort of the CEDAR-HCM pediatric study finished with results due in early 2027.
What to watch: European net product revenue in the fourth quarter as the United Kingdom launch begins. Early UK sales will show whether new country launches can offset slower reordering in Germany.
🐻 Bear Case
German Sales Dropped After Initial Stocking
While management highlighted international expansion to bring Myqorzo to more patients, revenue from Europe moved backward after its initial quarter. European net product revenue, which comes entirely from Germany, fell 39.1% from last quarter to $1.4 million by our math, down from $2.3 million in the second quarter.
Second-quarter German revenue reflected initial inventory stocking by distributors, so the third-quarter drop shows actual patient uptake in Germany is starting from a smaller base. In addition, product cost of goods sold was a negative $0.5 million because of a "credit related to drug supply optimization activities", meaning reported product gross margin is artificially high because of accounting credits and pre-approval inventory expensed in prior years.
What to watch: German revenue trends alongside underlying cost of goods sold once inventory credits end. A rebound in European revenue is needed to prove international markets can contribute meaningful profit.
Heavy Cash Burn and Debt Costs Persist
Headline net loss looked much smaller at $190.1 million versus $306.2 million a year ago, but last year included a one-time $121.2 million debt conversion charge. Excluding that one-off charge, the net loss widened by 2.8% from $184.9 million a year ago by our math, because commercial launch spending absorbed all of the new drug revenue.
- Selling and administrative expense: $113.1 million, up 62.9% from a year ago
- Non-cash royalty interest expense: $23.6 million, up 57.9% from a year ago
- Total cash and investments: $1.58 billion, down $120.4 million from June by our math
- Diluted share count: 139.0 million, up 15.9% from a year ago after May's stock offering
The company carries $1.87 billion in combined debt and royalty liabilities by our math, and its full-year expense plan points to an even larger spending jump in the fourth quarter. That means cash burn will stay high even as sales grow.
What to watch: fourth-quarter cash burn as combined research and commercial expenses step up to roughly $260 million. It will show how quickly product sales can narrow the quarterly cash drain.
Risks this quarter didn't answer
Several standing competitive, regulatory, and clinical risks were not addressed in the third-quarter earnings release or shifted further out in time.
- Share of new prescriptions against Bristol Myers Squibb's Camzyos and paid prescription rate: not in the release; the conference call will show whether share passed 40%.
- Safety monitoring rules and label expectations for the nHCM filing: not in the release; FDA filing acceptance in early 2027 will test how regulators view the 10% rate of reduced heart pumping function.
- MAPLE-HCM supplemental application for earlier-line use: no update ahead of the November 14, 2026 FDA target action date.
- Heart failure trial timelines: COMET-HF enrollment is now expected to continue through 2027 rather than finishing in 2026, while AMBER-HFpEF Cohort 1 enrollment is due in the fourth quarter of 2026.
- Shareholder class-action litigation over prior regulatory disclosures: no update in the release; the quarterly Form 10-Q legal footnote will carry any status change.
💲 Other KPIs
More than doubled from $6.5 million in June and $3.8 million in March, up 147.0% from last quarter by our math. Long-term inventories are drug supplies held for sale beyond the next twelve months. The company only began capitalizing inventory after regulatory approval, so this build ties up cash ahead of wider international launches.
Rose 57.5% from $1.9 million a year ago, but edged down 7.3% from $3.3 million in the second quarter by our math. Collaboration revenue comes from research reimbursements and drug supply manufacturing for partners Bayer and Sanofi. Collaboration costs were $2.7 million this quarter, so these partner reimbursements add very little net cash.
🔮 Guidance
Unchanged. The full-year spending plan still calls for combined research and commercial costs to rise about 25.0% from last year at the middle of the range. After $615.1 million spent in the first nine months, the outlook leaves $259.9 million for the fourth quarter by our math, a 22.4% jump from the third quarter as European launches and nHCM filing preparations ramp up.
Unchanged. Management kept its forecast for employee stock awards included inside research and commercial expenses at a $135.0 million middle of the range, following a $10 million raise last quarter. With $100.8 million recorded over the first nine months, the plan leaves $34.2 million for the fourth quarter by our math, compared with $34.7 million in the third quarter.
❓ Key Questions
What was Myqorzo's share of new prescriptions in Q3?
Management previously targeted more than 50% of new-to-brand prescriptions in its drug class by year-end after passing 40% in June, but the release omitted this figure and the percentage of patients on paid prescriptions.
How much of Q3 US sales came from inventory stocking?
While US sales growth matched cumulative dispensed patient growth at roughly 87%, management has not disclosed distributor weeks on hand or patient discontinuation rates.
Why did German revenue drop 39% after Q2's launch?
European revenue fell from $2.3 million in the second quarter to $1.4 million in the third quarter, raising questions about the pace of underlying patient demand in Germany once initial distributor stocking ended.
Is the November 14 FDA decision for MAPLE-HCM on track?
The supplemental application based on the MAPLE-HCM trial had a November 14, 2026 FDA target action date just ten days after the release, yet the update did not mention the pending decision.